Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.
In a putative animal model of antipsychotic drug-induced weight gain, female rats received either vehicle, ziprasidone (2.0, 6.0, 10 mg/kg) or olanzapine (2.0 mg/kg), orally, twice daily, for 7 days. Body weights were assessed daily and prolactin assayed at the end of the regimen. Ziprasidone caused significant weight gain, as did olanzapine, while stimulating distinct patterns of prolactin secretion. Thus, assessment of body weight provides only limited predictive validity in differentiating between weight gain-inducing and weight-neutral drugs.
Schizophrenia and Bipolar Disorders - In Vivo Biology, Psychiatry CEDD, GlaxoSmithKline PLC, New Frontiers Science Park, Harlow, Essex, UK. mikhail.m.kalinichev@gsk.com
Mikhail
M
Kalinichev
Claire
C
Rourke
Declan N C
DN
Jones
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects*; D005260:Female; D000077152:Olanzapine; D010879:Piperazines / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000494:pharmacology*; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D011388:Prolactin; D000077152:Olanzapine